Pfizer Inc. (NYSE:PFE) ranks among the best retirement stocks to buy now.
On May 5, BofA Securities boosted its price objective for Pfizer Inc. (NYSE:PFE) to $27 from $26, retaining a Neutral rating on the company shares
Following Pfizer’s first-quarter performance, the firm raised its fiscal 2026 revenue and earnings per share forecasts. The pharmaceutical giant reported adjusted earnings per share of $0.75, 4.17% more than the consensus forecast of $0.72, while revenue of $14.5 billion exceeded expectations of $13.84 billion by 4.77%. Ignoring COVID-related products, Pfizer’s core business increased by 7% operationally.
BofA remarked that Pfizer’s long-term revenue CAGR target for 2028-2033 is significantly higher than the consensus. BofA sees meeting this aim as questionable and potentially skewed toward obesity therapies, where the market landscape is very competitive. Additionally, Pfizer Inc. (NYSE:PFE) revealed details regarding a 35-valent pneumococcal conjugate vaccine that is ready for Phase 1.